Revelation Biosciences (REVB) Stock Price, News & Analysis

Company Overview

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.

Key Stats

• Today's Range: $2.37 to $2.92
• 50-Day Range: $2.24 to $9.78
• 52-Week Range: $2.11 to $168.00
• Volume: 856,875 shs
• Average Volume: 131,477 shs
• Market Capitalization: $4.37 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Revelation Biosciences Stock Analysis - MarketRank™

Revelation Biosciences scored higher than 10% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Revelation Biosciences.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Revelation Biosciences are expected to grow in the coming year, from ($49.33) to ($34.03) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Revelation Biosciences is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Revelation Biosciences is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Revelation Biosciences has a P/B Ratio of 0.11. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.54% of the float of Revelation Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Revelation Biosciences has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Revelation Biosciences has recently increased by 10.95%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Revelation Biosciences does not currently pay a dividend.

Dividend Growth

Revelation Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

7.54% of the float of Revelation Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Revelation Biosciences has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Revelation Biosciences has recently increased by 10.95%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: N/A

News Sentiment

Revelation Biosciences has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Revelation Biosciences this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Revelation Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.30% of the stock of Revelation Biosciences is held by insiders.

Percentage Held by Institutions

Only 12.80% of the stock of Revelation Biosciences is held by institutions.

REVB Stock Analysis - Frequently Asked Questions

How have REVB shares performed this year?

Revelation Biosciences' stock was trading at $22.1280 at the beginning of the year. Since then, REVB shares have decreased by 87.1% and is now trading at $2.85.

How were Revelation Biosciences' earnings last quarter?

Revelation Biosciences, Inc. (NASDAQ:REVB) released its earnings results on Thursday, May, 8th. The company reported ($6.33) EPS for the quarter, beating the consensus estimate of ($20.64) by $14.31.

When did Revelation Biosciences' stock split?

Revelation Biosciences's stock reverse split on Tuesday, January 28th 2025.The 1-16 reverse split was announced on Friday, January 24th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 27th 2025. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

How do I buy shares of Revelation Biosciences?

Shares of REVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Revelation Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Revelation Biosciences investors own include Predictive Oncology (POAI), Ford Motor (F), Wells Fargo & Company (WFC), Wayfair (W), Abbott Laboratories (ABT), JPMorgan Chase & Co. (JPM) and Bank of America (BAC).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/09/2025
• Next Earnings (Estimated): 8/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:REVB
• CIK: 1810560
• Web: www.revbiosciences.com
• Phone: 650-800-3717
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($102.61)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$15.04 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -299.46%
• Return on Assets: -115.36%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.60
• Quick Ratio: 3.60

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $27.05 per share
• Price / Book: 0.11

Miscellaneous

• Outstanding Shares: 1,530,000
• Free Float: 1,499,000
• Market Cap: $4.36 million
• Optionable: Not Optionable
• Beta: -0.08